Systematic Discovery of Molecular Glues Targets Protein Degradation in Leukemia
•February 16, 2026
0
Why It Matters
The approach transforms molecular‑glue discovery into a reproducible, scalable process, offering new therapeutic avenues for cancers and other diseases driven by traditionally undruggable targets.
Key Takeaways
- •High-throughput ligand diversification enables rapid molecular glue discovery
- •ENL degradation suppresses growth of leukemia cells
- •Cellular screening bypasses need for protein purification
- •Cooperative binding creates selective ubiquitin ligase recruitment
- •Approach could expand druggable proteome for undruggable targets
Pulse Analysis
Molecular glues have emerged as a powerful class of therapeutics that co‑opt the cell’s ubiquitin‑proteasome system to eliminate disease‑causing proteins. Historically, their discovery relied on serendipity, limiting the ability to target the vast majority of proteins deemed "undruggable." By integrating combinatorial chemistry with functional readouts in live cells, the new platform sidesteps the bottleneck of protein purification and accelerates the identification of compounds that can forge novel protein‑protein interfaces.
The AITHYRA team applied this workflow to ENL, a transcriptional regulator essential for certain acute leukemias. Thousands of chemically diversified analogs were generated from a known ENL binder, then screened for degradation activity using a sensitive cellular assay. One molecule emerged that not only triggered rapid ENL depletion but also demonstrated high selectivity, sparing unrelated proteins and markedly reducing leukemia cell proliferation. Mechanistic studies revealed a cooperative binding mode: the compound first engages ENL, reshaping its surface to recruit a specific ubiquitin ligase, thereby achieving precise proteasomal tagging.
Beyond the ENL case study, the methodology signals a paradigm shift for drug discovery. By making proximity‑inducing chemistry systematic, researchers can now explore vast chemical spaces with direct functional feedback, potentially unlocking therapeutic options for a wide array of diseases where traditional inhibition fails. Pharma pipelines are likely to incorporate such high‑throughput, cell‑based screens to expand the druggable proteome, accelerating the translation of molecular‑glue concepts into clinically viable treatments.
Systematic Discovery of Molecular Glues Targets Protein Degradation in Leukemia
Cells monitor and recycle their proteins through a tightly regulated waste-disposal system. Proteins that are no longer needed are tagged and broken down by specialized cellular machinery. Recent advances in drug discovery seek to exploit this system by redirecting it toward disease-relevant targets.
One strategy relies on molecular glues—small molecules that induce interactions between proteins that would not normally bind to each other. If a disease-causing protein can be brought into contact with a cellular degradation enzyme, it is selectively eliminated by the cell itself.
A new method took a systematic approach to the discovery of new molecular glues: starting from a small molecule that already binds to a target protein, researchers generated thousands of chemical variants by systematically attaching different molecular building blocks. Each variant subtly reshapes the surface of the protein, potentially enabling new protein–protein interactions.
The compounds were screened directly in living cells, without prior purification, using a sensitive assay that reports whether the target protein is being degraded. This enabled rapid identification of active compounds from a vast chemical space.
This work is published in Nature Chemical Biology in the paper, “High-throughput ligand diversification to discover chemical inducers of proximity.”
“Our approach combines high-throughput chemistry with functional testing in cells,” says Miquel Muñoz i Ordoño, a PhD student in the lab of Georg Winter, scientific director at the AITHYRA Research Institute for Biomedical Artificial Intelligence and adjunct principal investigator at the CeMM Research Center for Molecular Medicine in Vienna, Austria. “This allows us to explore chemical diversity at a scale that was previously impractical, while immediately seeing which compounds have a desired biological effect.”
The researchers focused on ENL, a protein that plays a central role in certain forms of acute leukemia. From several thousand tested compounds, the team identified a molecule that efficiently and selectively triggers degradation of ENL in leukemia cells. Further analyses showed that the compound primarily affects ENL and downstream gene programs controlled by this protein, leading to a strong reduction in the growth of ENL-dependent leukemia cells. They also revealed that the compound acts through a cooperative mechanism characteristic of molecular glues. Rather than binding strongly to all interaction partners, it first binds ENL and then creates a new interaction surface that recruits a cellular ubiquitin ligase, which marks ENL for degradation.
“This cooperative mode of action is what makes molecular glues both powerful and selective,” explains Winter. “The compound only becomes active in the right molecular context, which helps limit unwanted effects.”
Beyond the specific example of ENL, the study demonstrates a broadly applicable discovery strategy. By combining high-throughput chemistry with functional screening in cells, the researchers show how the identification of molecular glues can be transformed from a serendipitous process into a systematic workflow.
“Our goal is to make proximity-inducing drugs discoverable in a rational and scalable way,” says Winter. “In the long term, this could open up entirely new therapeutic opportunities for proteins that were previously considered undruggable.”
The post Systematic Discovery of Molecular Glues Targets Protein Degradation in Leukemia appeared first on GEN - Genetic Engineering and Biotechnology News.
0
Comments
Want to join the conversation?
Loading comments...